adacolumn + infliximab

**Adacolumn + infliximab** is an investigational combination therapy used in treatment-refractory inflammatory bowel diseases, particularly ulcerative colitis and Crohn's disease. Adacolumn is a medical device that performs granulocyte and monocyte apheresis—a blood filtration strategy that selectively removes activated granulocytes and monocytes/macrophages from circulation, thus reducing systemic and mucosal inflammation. It works via adsorption of Fc gamma receptor-bearing myeloid cells and complement-activated cells, decreasing the overall burden of proinflammatory leukocytes and cytokines, while sparing lymphocytes. Infliximab is a chimeric monoclonal antibody that binds with high affinity to tumor necrosis factor alpha (TNF-α), neutralizing its pro-inflammatory effects. The combination is explored for cases with lost or inadequate response to standard therapies, including scenarios where sequential or additive immunomodulation is sought. Clinical use is based mainly on pragmatic needs in severe or refractory inflammatory bowel disease, and high-quality evidence for the safety and efficacy of this particular combination remains limited, relying largely on observational reports and expert opinions[2][3][4][5].